425 Metro Place N Publicly Traded

Suite 300
Dublin, OH 43017 Market Cap: $47 million
OTC BB: NEOP
Phone: (614) 793-7500
Fax: (614) 793-7520 Incorporated 1983
21 Employees

www.neoprobe.com

Highlights

Recent Anticipated

¾ Presented final Phase 2 clinical data at March ’08 ¾ Closing of final $3 million investment from Platinum-
SSO meeting (99% success rate). Montaur Life Sciences, LLC.

¾ Initiated patient enrollment activities in a Phase 3
®
clinical study to evaluate the efficacy of Lymphoseek in
patients with breast cancer or melanoma.
¾ Submitted a protocol design for a Phase 3 clinical
study to evaluate the efficacy of Lymphoseek in patients
with head and neck squamous cell carcinoma.
¾ Completed $10 million of a total planned $13 million
investment from Platinum-Montaur Life Sciences, LLC.
¾ Completed exclusive marketing and distribution
agreement for Lymphoseek in the United States with
Cardinal Health.
¾ Extended global marketing and distribution agreement
for gamma detection devices with Ethicon Endo-Surgery,
Inc. (J&J) with improved business terms to Neoprobe.
¾ Initiation of Phase 3 trial for Lymphoseek in head and
neck squamous cell carcinoma.
¾ Completion of two Phase 3 multi-center clinical studies
for Lymphoseek in breast, melanoma, and in head and
neck squamous cell carcinoma. NDA for Lymphoseek
will be filed approximately 120 days after successful
completion of the Phase 3 studies.
¾ Scientific advice application filed for Lymphoseek with
EMEA and scientific advice meeting scheduled for
second quarter 2008 to finalize EU product registration
requirements.
¾ Scientific advice decision expected regarding
RIGScan® CR in 3Q ’08 followed by reactivation of
development alliance / funding efforts.

Corporate Mission

Neoprobe Corporate is a biomedical company that develops and commercializes innovative medical
products that enhance patient care and improve patient outcome. Neoprobe’s product portfolio includes
innovative cardiovascular and surgical oncology products. Neoprobe has initiated late stage clinical trials
in 2008 for a cancer diagnostic drug. The diagnostic drug, Lymphoseek, will be a first in class for
lymphatic tissue targeting. Neoprobe also has a therapeutic drug, RIGScan CR, in development that is
designed to improve survival in colorectal cancer patients.

Proprietary Technology

Neoprobe is actively marketing two medical device product lines while it pursues development initiatives
for three potentially significant drug/therapeutic products. Neoprobe’s drug/therapeutic development
efforts are centered on two radiopharmaceutical agents, Lymphoseek and RIGScan CR, and on the
activated cellular therapy (ACT) technology platform of Neoprobe’s subsidiary, Cira Biosciences, Inc.
(Cira Bio).

Lymphoseek is commencing Phase 3 clinical studies, and if approved, would be a first in class drug
specifically labeled for use in a procedure commonly referred to as intraoperative lymphatic mapping
(ILM) or sentinel lymph node biopsy (SLNB). Neoprobe has completed a revenue sharing
marketing/distribution agreement for Lymphoseek in the U.S. with Cardinal Health.

Neoprobe Information Sheet 16May2008 Page 1

RIGScan CR is a tumor-specific targeting agent initially intended for use in treatment of colorectal cancer.
RIGScan CR has shown promising results in earlier clinical trials and Neoprobe is focusing its current
efforts surrounding RIGS on identifying and securing a development partner and on preparing a request
for a special protocol assessment to prepare for future clinical evaluations.

Neoprobe’s device offerings are led by the neo2000® line of gamma detection systems widely used by
cancer surgeons in ILM for the diagnosis and treatment of cancer and related diseases. Neoprobe’s
gamma detection system offerings also now include wireless probes based on Bluetooth® technology.
Additionally, Neoprobe is commercializing the Quantix® line of blood flow measurement products. The
Quantix products employ a unique and proprietary dual beam Doppler technology that permits real-time,
accurate measurement of volume blood flow and other hemodynamic parameters.

Current Alliances

¾ Ethicon Endo-Surgery, Inc. (a Johnson and Johnson Company) – worldwide (excluding Japan)
marketing of Neoprobe’s gamma detection products
¾ Century Medical Products – marketing of Neoprobe’s gamma detection products in Japan
¾ Cardinal Health – marketing and distribution of Lymphoseek in the U.S.
¾ The Dow Chemical Company – development and licensing of proprietary cancer targeting agents
¾ ESTECH, Inc. – master distributor for Cardiosonix products in the U.S. and European Union
University of California, San Diego – development of proprietary radiopharmaceuticals and tissue
targeting technology

Intellectual Property Status

Neoprobe owns or licenses over forty issued patents in the United States, European Union and Japan.
These patents primarily cover key aspects of Neoprobe’s gamma detection devices and blood flow
measurement devices. In addition, concept of matter patents cover Lymphoseek and RIGScan CR.
Finally, patents have been issued that cover the methodology behind Neoprobe’s activated cellular
therapy in oncology and autoimmune applications. Additional patents are pending.

Products

Name Indication Phase Milestone

neo2000 Intraoperative detection of 510(k) approved & CE Worldwide commercial
radiolabeled pharmaceuticals Mark clearance brand leader

Quantix/OR Intraoperative and non- 510(k) approved & CE Worldwide commercial

invasive measurement of Mark clearance sales
blood flow & estimation of
cardiac output

Lymphoseek Intraoperative identification of Phase 3 in U.S. & EU Commencement of

predictive disease involved Phase 3 in 2Q 2008
lymph node – breast cancer,
melanoma and other solid
tumors

RIGScan CR Colorectal cancer Open BLA w/ FDA & Meeting w/ FDA &
EMEA clinical strategy EMEA in mid-2008
pending

Activated Cellular Colorectal and breast Phase 2 Completion of funding

Therapy (ACT) cancers; HIV program for Cira Bio

Neoprobe Information Sheet 16May2008 Page 2